Prime Medicine (PRME) Tax Provisions (2021 - 2024)

Prime Medicine (PRME) has 4 years of Tax Provisions data on file, last reported at -$134000.0 in Q2 2024.

• Quarterly Tax Provisions fell 532.26% year-over-year to -$134000.0 in Q2 2024, while the trailing twelve-month figure through Mar 2025 was -$134000.0 (down 335.09% YoY) and the FY2023 annual result came in at -$279000.0, up 70.57% from the prior year.
• Tax Provisions slipped to -$134000.0 in Q2 2024, from $134000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $1.4 million in Q4 2021 to a low of -$2.4 million in Q3 2021.
• A 4-year average of -$201454.5 and a median of -$134000.0 in 2024 frame the typical range for Tax Provisions.
• The widest YoY moves for Tax Provisions: up 166.34% in 2024, down 532.26% in 2024.
• Tracing PRME's Tax Provisions over 4 years: stood at $1.4 million in 2021, then plunged by 113.47% to -$186000.0 in 2022, then jumped by 41.94% to -$108000.0 in 2023, then decreased by 24.07% to -$134000.0 in 2024.
• The last three Tax Provisions figures came in at -$134000.0 (Q2 2024), $134000.0 (Q1 2024), and -$108000.0 (Q3 2023), per Business Quant data.